Everolimus breast cancer use patent considered valid in preliminary injunction proceedings in Italy and then upheld at first instance in the EPO
On 9 July 2021, the Court of Milan issued a preliminary injunction (PI) prohibiting a generic company from selling everolimus for use in combination with an aromatase inhibitor in the treatment of hormone receptor positive breast tumours. The PI was issued on the basis of EP 3351246, which is one of the patents held by…